Skip to main
AVXL

AVXL Stock Forecast & Price Target

AVXL Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Anavex Life Sciences Corp demonstrates a positive outlook due to its commitment to addressing tolerability concerns in its investigational therapies, which has resulted in lower discontinuation rates in clinical trials. The company's latest Phase 2b/3 oral blarcamesine trial revealed a significant improvement in patient outcomes, with treatment providing an approximate 17.8 months of time saved compared to controls. Furthermore, enhancements in manufacturing processes and a revised ten-week titration protocol are expected to solidify the case for its Alzheimer's therapy during regulatory submissions and advance the company's overall position in the biopharmaceutical market.

Bears say

Anavex Life Sciences Corp faces a challenging outlook following the recent negative opinion issued by the Committee for Medicinal Products for Human Use (CHMP) regarding the Marketing Authorisation Application for its lead compound, blarcamesine. The probability of success for the company's therapeutic models has been significantly lowered, with estimates for the US at 50% and EU at 15%, indicating increased uncertainty surrounding regulatory approval. Compounding these risks are high treatment-discontinuation rates from central nervous system-related side effects, which could hinder the interpretation of clinical data and ultimately impede the company's growth prospects.

AVXL has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Anavex Life Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Anavex Life Sciences (AVXL) Forecast

Analysts have given AVXL a Strong Buy based on their latest research and market trends.

According to 2 analysts, AVXL has a Strong Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Anavex Life Sciences (AVXL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.